Piscataway-based Camber Pharmaceuticals is recalling Atovaquone Oral Suspension, a medication used to treat the Pneumocystis jiroveci pneumonia (PCP) fungal infection in patients ages 13 and older.
The company issued the recall March 14 of lot No. E220182 of Atovaquone Oral Suspension, USP 750mg/5mL, because of potential Bacillus cereus contamination.
In immunocompromised individuals, the microbial contamination could lead to life-threatening infections such as endocarditis and necrotizing soft tissue infections. However, Camber has not received any reports of adverse events related to this recall to date, the company emphasized.
The recalled Atovaquone was distributed nationwide to wholesalers, distributors, retail pharmacies and mail-order pharmacies, all of whom Camber is notifying and arranging for returns. The U.S. Food and Drug Administration also is aware of the recall.
The product is packaged in 210mL HDPE bottle in a mono carton. The identified NDC # associated with the product is 31722-629-21, UPC # 331722629218, and the affected lot# is E220182 with an expiration date of 12/2023.
Anyone with the recalled product should stop using it, return it to where they purchased it, discard it or contact their doctor.